[go: up one dir, main page]

WO2008152423A3 - Treatment of inflammation or autoimmune diseases with sulphated compounds - Google Patents

Treatment of inflammation or autoimmune diseases with sulphated compounds Download PDF

Info

Publication number
WO2008152423A3
WO2008152423A3 PCT/GB2008/050437 GB2008050437W WO2008152423A3 WO 2008152423 A3 WO2008152423 A3 WO 2008152423A3 GB 2008050437 W GB2008050437 W GB 2008050437W WO 2008152423 A3 WO2008152423 A3 WO 2008152423A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
relates
dosage forms
unit dosage
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/050437
Other languages
French (fr)
Other versions
WO2008152423A2 (en
Inventor
Michael Peter Seed
Joe Albert Mancini
Laura Dugo
Margaret Lees
Michael Burnet
Hans Juergen Gutke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DIOSAMINE DEV CORP
Original Assignee
DIOSAMINE DEV CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DIOSAMINE DEV CORP filed Critical DIOSAMINE DEV CORP
Publication of WO2008152423A2 publication Critical patent/WO2008152423A2/en
Publication of WO2008152423A3 publication Critical patent/WO2008152423A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to sulphated compounds containing one to twelve monosaccharide subunits, for the treatment or prevention of anon-gastrointestinal disease or conditionby gastrointestinal absorption, wherein none of the monosaccharide subunits is pyranosyl with N-substitution at the 2-position relative to the anomeric carbon of the pyranosyl subunit. The present invention also relates to corresponding methods of treating or preventing anon-gastrointestinal disease or condition. Additionally, the present invention relates to a method of modifying, or testing for a modification in,the level of a cytokine in vivo, ex vivoor in vitro, said method comprising contacting a sulphated compound with a cell, wherein the compound comprises at least one monosaccharide subunit. The present invention also relates to unit dosage forms comprising at least 2.5g of any of the above compounds, to unit dosage forms comprising the molar equivalent of at least 1 g of any of the above compounds in theirfree acid and/or base form, and to unit dosage forms comprising any of the above compounds other than sucralfate.Preferred compounds of the present invention are sucrose octasulphate and sucralfate.
PCT/GB2008/050437 2007-06-11 2008-06-11 Treatment of inflammation or autoimmune diseases with sulphated compounds Ceased WO2008152423A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0711139A GB2450087A (en) 2007-06-11 2007-06-11 Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
GB0711139.6 2007-06-11

Publications (2)

Publication Number Publication Date
WO2008152423A2 WO2008152423A2 (en) 2008-12-18
WO2008152423A3 true WO2008152423A3 (en) 2009-02-19

Family

ID=38319060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050437 Ceased WO2008152423A2 (en) 2007-06-11 2008-06-11 Treatment of inflammation or autoimmune diseases with sulphated compounds

Country Status (2)

Country Link
GB (1) GB2450087A (en)
WO (1) WO2008152423A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201000196D0 (en) 2010-01-07 2010-02-24 Galvez Julian M Novel combination
HUE043546T2 (en) * 2010-12-01 2019-08-28 Univ Australian National use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028020A1 (en) * 1993-05-18 1994-12-08 Bukh Meditec A/S A method for the preparation of interferons
WO1996035700A1 (en) * 1995-05-10 1996-11-14 Glycomed Incorporated Saccharopeptides and derivatives thereof
US5908836A (en) * 1987-12-21 1999-06-01 Bar-Shalom; Daniel Protecting skin from radiation damage using sulphated sugars
WO2006017752A2 (en) * 2004-08-05 2006-02-16 Ivax Corporation Sulfated oligosaccharides
WO2008059003A1 (en) * 2006-11-14 2008-05-22 Diosamine Development Corporation Novel compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK505488D0 (en) * 1987-12-21 1988-09-09 Bar Shalom Daniel MEDIUM AND USE OF SAME
IT1226549B (en) * 1988-07-12 1991-01-24 Resa Farma PHARMACEUTICAL COMPOSITIONS WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY FOR ORAL USE, EQUIPPED WITH EXCELLENT PALATABILITY AND FREE FROM IRRITATING EFFECTS ON MUCOSES.
JP2000143686A (en) * 1997-02-28 2000-05-26 Agency Of Ind Science & Technol Sulfated oligosaccharide compound
JP3163358B2 (en) * 1997-02-28 2001-05-08 経済産業省産業技術総合研究所長 Sulfated oligosaccharide compounds
US20040039042A1 (en) * 2002-08-23 2004-02-26 Fleming Thomas E. Method of transdermal drug delivery
JP4850402B2 (en) * 2004-10-07 2012-01-11 ロート製薬株式会社 Oral preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908836A (en) * 1987-12-21 1999-06-01 Bar-Shalom; Daniel Protecting skin from radiation damage using sulphated sugars
WO1994028020A1 (en) * 1993-05-18 1994-12-08 Bukh Meditec A/S A method for the preparation of interferons
WO1996035700A1 (en) * 1995-05-10 1996-11-14 Glycomed Incorporated Saccharopeptides and derivatives thereof
WO2006017752A2 (en) * 2004-08-05 2006-02-16 Ivax Corporation Sulfated oligosaccharides
WO2008059003A1 (en) * 2006-11-14 2008-05-22 Diosamine Development Corporation Novel compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURCH R M ET AL: "Sucralfate induces prolifetion of dermal fibroblasts and keratinocytes in culture and granulation tissue formation in full-thickness skin wounds", AGENTS AND ACTIONS, BIRKHAEUSER VERLAG, BASEL, CH, vol. 34, no. 1-2, 1 January 1991 (1991-01-01), pages 229 - 231, XP002962047, ISSN: 0065-4299 *
CAHALON LIORA ET AL: "Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents", INTERNATIONAL IMMUNOLOGY, vol. 9, no. 10, 1997, pages 1517 - 1522, XP002504319, ISSN: 0953-8178 *
EAMLAMNAM K ET AL: "Effects of Aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats", WORLD JOURNAL OF GASTROENTEROLOGY, WJG PRESS, CN, vol. 12, no. 13, 7 April 2006 (2006-04-07), pages 2034 - 2039, XP008098731, ISSN: 1007-9327 *
SCHOELL ISABELLA ET AL: "Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring", FASEB JOURNAL, vol. 21, no. 4, April 2007 (2007-04-01), pages 1264 - 1270, XP002504320, ISSN: 0892-6638 *
SLOMIANY B L ET AL: "Effect of sucralfate on gastric mucosal inflammatory responses induced by Helicobacter pylori lipopolysaccharide", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 33, no. 9, September 1998 (1998-09-01), pages 916 - 922, XP008095949, ISSN: 0036-5521 *

Also Published As

Publication number Publication date
GB0711139D0 (en) 2007-07-18
WO2008152423A2 (en) 2008-12-18
GB2450087A (en) 2008-12-17

Similar Documents

Publication Publication Date Title
AU634199B2 (en) Heparin fragments as inhibitors of smooth muscle cell proliferation
NO20084931L (en) Pharmaceutical compositions
CN107708704A (en) Microorganism group conditioning agent and its associated uses
WO2007128480A3 (en) Thioglycosides as pharmaceutically active agents
EP1911453A3 (en) Immunemodulating oligosaccharides
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
KR20090109104A (en) Low molecular weight heparin comprising one or more covalent bonds with biotin or biotin derivatives, methods for their preparation and uses thereof
MX2007012045A (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient.
WO2008152423A3 (en) Treatment of inflammation or autoimmune diseases with sulphated compounds
ES2731582T3 (en) N-desulphated glycosaminoglycan derivatives and their use as drugs
WO2008096547A1 (en) Anti-tumor composition comprising tissue-accumulating chitosan gel
EP2298336A3 (en) Promotion of epithelial regeneration
JP2004536825A5 (en)
WO2007109731A3 (en) Healing powder and method of use thereof
WO2008061671A3 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
EP1561760A3 (en) Low molecular weight heparin salt with thriethanolamine
EP2515910B1 (en) Use of polysaccharides in the treatment of stress and anxiety
WO2007059010A3 (en) Stem cell factor therapy for tissue injury
US20230102826A1 (en) Heparanase inhibitors for treatment of diabetes
US20220233578A1 (en) Compositions and methods of using same for tissue regeneration
EP2301554A1 (en) Composition for the treatment of osteoarthritis
Heitlinger et al. Transport of glucose polymer-derived glucose by rabbit jejunum
AU714164B2 (en) Modified pectin material
JP2005509007A5 (en)
WO2009135455A3 (en) Method for producing gemcitabine hydrochloride and intermediate products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08762547

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08762547

Country of ref document: EP

Kind code of ref document: A2